Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)

Prior treatment

• Condition or chronic illness, which in the opinion of the PI/Co-I, makes participation unsafe or untenable (i.e., cognitive impairment, concurrent acute morbidity).

Other

• Participants who are unable to converse fluently in English will be excluded.
• Inability or unwillingness of research participant to give verbal informed consent.
• Participants who lack access to a computer or mobile device that supports video communications will be excluded.

• For Group 1 participants only (Undergone Gene Therapy):
  • Parent/caregiver whose child has undergone gene therapy. OR Parent/caregiver of a child who died after receiving gene therapy at least 6 months prior to enrollment, but no more than 24 months prior to enrollment, to be contacted no sooner than 3 months after the death has occurred and no longer than 2 years. OR Patients age 8 and above who have undergone gene therapy.
  • Willingness to participate in one-on-one video interview with a study team member using a personal mobile device or computer with working internet connection.
  • Must be willing to provide verbal informed consent.
  • Release of information form signed by participant providing our study team with permission to contact healthcare provider to verify their diagnosis and receipt of gene therapy (if received).
  • Successful verification of diagnosis of rare genetic disease targeted for treatment using gene therapy.
  • A positive confirmation on receipt of gene therapy and type received from their healthcare provider (only for those received gene therapy).
• For Group 2 participants only (Offered, but did not Undergo Gene Therapy):
  • Parent/caregiver of children (or patients 8 and above ) with a rare genetic disease who had been offered but were not eligible for a trial or decided against receiving gene therapy.
  • Willingness to participate in one-on-one video interview with a study team member using a personal mobile device or computer with working internet connection.
  • Must be willing to provide verbal informed consent.
  • Signed release of information form providing GeneTx study team with permission to contact participant's healthcare provider to verify the diagnosis.
  • Successful verification of diagnosis of rare genetic disease targeted for treatment using gene therapy.
• For Group 3 participants only (Provider Interviews):
  • Healthcare worker who has provided care to ≥ 2 patients receiving gene therapy.
  • Willingness to participate in one-on-one video (or in-person) interview with a study team member using a personal mobile device or computer with working internet connection.
  • Informed consent from a study participant.
• For Group 4 participants only (Undergone Gene Therapy for Bone Marrow Failure Condition):
  • Parent/caregiver whose child has undergone gene therapy. OR Parent/caregiver of a child who died after receiving gene therapy at least 6 months prior to enrollment, but no more than 24 months prior to enrollment, to be contacted no sooner than 3 months after the death has occurred and no longer than 2 years. OR Patients age 8 and above who have undergone gene therapy.
  • Willingness to participate in one-on-one video interview with a study team member using a personal mobile device or computer with working internet connection.
  • Must be willing to provide verbal informed consent.
  • Release of information form signed by participant providing our study team with permission to contact healthcare provider to verify their diagnosis and receipt of gene therapy (if received).
  • Successful verification of diagnosis of rare genetic disease targeted for treatment using gene therapy.
  • A positive confirmation on receipt of gene therapy and type received from their healthcare provider (only for those received gene therapy).
• For Group 5 participants only (Offered, but did not Undergo Gene Therapy for Bone Marrow Failure Condition ):
  • Parent/caregiver of children (or patients 8 and above ) with a bone marrow failure disease who had been offered but were not eligible for a trial or decided against receiving gene therapy.
  • Willingness to participate in one-on-one video interview with a study team member using a personal mobile device or computer with working internet connection.
  • Must be willing to provide verbal informed consent.
  • Signed release of information form providing GeneTx study team with permission to contact participant's healthcare provider to verify the diagnosis.
  • Successful verification of diagnosis of rare genetic disease targeted for treatment using gene therapy.
• For Group 6 participants only (Never offered gene therapy for Bone Marrow Failure Condition):
  • Parent/caregiver of children (or patients 8 and above ) with a bone marrow failure disease who had not been offered gene therapy.
  • Willingness to participate in one-on-one video interview with a study team member using a personal mobile device or computer with working internet connection.
  • Must be willing to provide verbal informed consent.
  • Signed release of information form providing GeneTx study team with permission to contact participant's healthcare provider to verify the diagnosis.
  • Successful verification of diagnosis of rare genetic disease targeted for treatment using gene therapy.
• For Group 7 participants only (Provider Interviews for Bone Marrow Failure Condition):
  • Healthcare worker who has provided care to ≥ 2 patients receiving gene therapy.
  • Willingness to participate in one-on-one video (or in-person) interview with a study team member using a personal mobile device or computer with working internet connection.
  • Informed consent from a study participant.